14-3-3η Cytokine as a New Rheumatoid Arthritis Activity Assessing Biomarker
-
Published:2023-01-01
Issue:1
Volume:109
Page:46-60
-
ISSN:2658-655X
-
Container-title:Российский физиологический журнал им И М Сеченова
-
language:
-
Short-container-title:Rossijskij fiziologičeskij žurnal im. I.M. Sečenova
Author:
Korolkova A. A.1, Shevaldina M. E.2, Rybakov A. V.32, Ballyzek M. F.4, Vavilova T. V.5, Maslyansky A. L.5, Vasiliev D. S.3, Kozlova D. I.3, Khizha V. V.3, Yurieva K. A.6
Affiliation:
1. Pitirim Sorokin Syktyvkar State University 2. Peter the Great St.Petersburg Polytechnic University 3. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences 4. St. Petersburg Clinical Hospital of the Russian Academy of Sciences 5. Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation 6. St. Petersburg State University
Abstract
Currently, rheumatoid arthritis routine diagnosis includes joint syndrome indicator determination such as tender and swollen joints count, as well as a number of laboratory indicators. The most interesting are the second ones, which include rheumatoid factor, antibodies to cyclic citrullinated peptide and a some acute-phase indicators, but they have low sensitivity and specificity, especially in the disease early stages, when it is still possible to normalize bring the age-norm indicators and get stable disease remission. Additionally, some of these medical tests are expensive enough and compulsory health insurance not-included. But, most importantly, there are no reliable rheumatologist modern practice disease activity assessing tools depending on the current-used treatment strategy. The article evaluates 14-3-3η protein usage possibility as a promising biomarker for rheumatoid arthritis immuno-inflammatory process activity in joints assessment. It was shown a higher studied indicator informative value (in terms of accuracy, sensitivity, specificity) in comparison with traditional acute-phase indicators, such as the erythrocyte sedimentation rate and C-reactive protein.
Publisher
The Russian Academy of Sciences
Reference37 articles.
1. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheumat Disease 69(4): 631–637. https://doi.org/10.1136/ard.2009.123919 2. Karateev DE, Olunin YA (2008) About classification of rheumatoid arthritis. Rheumatol Sci Pract 5. https://doi.org/10.14412/1995-4484-2008-848 3. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg J, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheumat Disease 76: 960–977. https://doi.org/10.1136/annrheumdis-2016-210715 4. Fransen J, Stucki G, van Riel P (2003) Rheumatoid arthritis measures: Disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (radar), and rheumatoid arthritis disease activity index (Radai). Arthrit & Rheumat 49(S5): S214–S224. https://doi.org/10.1002/art.11407 5. Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthrit & Rheumat 38(1): 44–48. https://doi.org/10.1002/art.1780380107
|
|